Heart failure
Conditions
Interventions
Observation group:N/A
Sponsors
Chinese Academy of Medical Sciences Fuwai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: According to the National Heart Failure Guidelines 2023, National Cardiomyopathy Center Accreditation Standards, and the China Hypertrophic Cardiomyopathy Guidelines 2022, inpatients with heart failure and non-ischemic cardiomyopathy (including familial dilated cardiomyopathy, arrhythmogenic cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, Fabry disease, Danon disease, Pompe disease, muscular dystrophy, hemochromatosis, acromegaly, mitochondrial disease, and malform syndrome) were continuously enrolled.
Exclusion criteria
Exclusion criteria: The investigators identified medical conditions that were inappropriate for the study, including drug or alcohol abuse or severe mental illness, that prevented patients from complying with the protocol or follow-up procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 years of fatal all-cause events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular death;Hospitalisation for worsening heart failure;Heart transplant or left ventricular assist device implantation;Cardiovascular hospitalisation;Cardiovascular death or hospitalisation for worsening heart failure; | — |
Countries
China
Contacts
Public ContactZhang Jian
Chinese Academy of Medical Sciences Fuwai Hospital
Outcome results
None listed